Structure of the Active N-terminal Domain of Ezrin

CONFORMATIONAL AND MOBILITY CHANGES IDENTIFY KEYSTONE INTERACTIONS*

William James SmithDagger , Nicolas NassarDagger §, Anthony Bretscher||, Richard A. CerioneDagger **, and P. Andrew KarplusDagger Dagger §§

From the Dagger  Departments of Chemistry and Chemical Biology,  Molecular Biology and Genetics, and ** Molecular Medicine, Cornell University, Ithaca, New York 14853 and the Dagger Dagger  Department of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon 97331

Received for publication, October 16, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ezrin is a member of the ERM (ezrin, radixin, moesin) family of proteins that cross-link the actin cytoskeleton to the plasma membrane and also may function in signaling cascades that regulate the assembly of actin stress fibers. Here, we report a crystal structure for the free (activated) FERM domain (residues 2-297) of recombinant human ezrin at 2.3 Å resolution. Structural comparison among the dormant moesin FERM domain structure and the three known active FERM domain structures (radixin, moesin, and now ezrin) allows the clear definition of regions that undergo structural changes during activation. The key regions affected are residues 135-150 and 155-180 in lobe F2 and residues 210-214 and 235-267 in lobe F3. Furthermore, we show that a large increase in the mobilities of lobes F2 and F3 accompanies activation, suggesting that their integrity is compromised. This leads us to propose a new concept that we refer to as keystone interactions. Keystone interactions occur when one protein (or protein part) contributes residues that allow another protein to complete folding, meaning that it becomes an integral part of the structure and would rarely dissociate. Such interactions are well suited for long-lived cytoskeletal protein interactions. The keystone interactions concept leads us to predict two specific docking sites within lobes F2 and F3 that are likely to bind target proteins.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The ERM1 (ezrin (1,2)/radixin (3,4)/moesin (5)) family of proteins serve as regulated cross-linkers between the actin cytoskeleton and the plasma membrane (reviewed in Refs. 6 and 7). Ezrin, radixin, and moesin are found in vertebrates as highly similar paralogs (~75% sequence identity) that differ in their primary tissue distributions but probably have a large degree of functional equivalence. In addition to binding to actin filaments and membrane proteins like CD44 (8) and ICAM2 (9), members of the ERM family appear to function in cell signaling as they interact with several signaling molecules, including the 85-kDa regulatory subunit of PI3-kinase (designated p85) (10), the multifunctional regulator, RhoGDI (11), EBP50 (12), and the tumor suppressor, hamartin (13). At least some of these various binding activities are regulated by a masking/unmasking phenomenon (14), and it is becoming apparent that such a mechanism is a theme common to many cytoskeletal proteins such as vinculin (15, 16), Wiscott-Aldrich syndrome protein (17), and formins (18). Our structural and functional studies of the ERM proteins are aimed at elucidating the details of this type of regulation.

The ~65-kDa ERM proteins consist of three functional domains: an amino-terminal 300-residue FERM domain (band four-point one, ezrin, radixin, moesin homology domains) that is responsible for binding to membrane proteins and many signaling proteins (reviewed in Ref. 7), a central 200-residue putative coiled-coil region that when phosphorylated on Tyr-353 contributes to an interaction with p85 (10), and a carboxyl-terminal 100-residue auto-inhibitory carboxyl-terminal tail domain (also known as the C-ERMAD) that contains the F-actin binding site (19, 14). In resting cells, ERM proteins are in a dormant state characterized by an intramolecular association of the FERM and tail domains. This dormant state has no known binding partners except perhaps the regulatory subunit of protein kinase-A (20), although additional partners cannot be ruled out. One pathway of activation (i.e. release of the FERM-tail interaction) of the ERM proteins appears to be triggered by phosphorylation of a specific threonine in the tail domain (Thr-558 in moesin) by the Rho-associated kinase (21) and the protein kinase C-Theta (22, 23) and/or the association with the phosphotidylinositol lipid, PIP2 (24, 25).

Our structural understanding of ERM function was given a solid foundation with the determination of the crystal structure for a dormant moesin FERM-tail complex (26). It revealed that the FERM domain is a clover-shaped molecule consisting of three structural domains (lobes F1, F2, and F3). Residues 2-82 (lobe F1) possess a ubiquitin-like fold, residues 83-195 (lobe F2) fold into a topology like that of acyl-CoA-binding protein (27), and residues 196-297 (lobe F3) adopt the pleckstrin homology/phosphotyrosine binding fold found in a broad range of signaling molecules, including dynamin, Sos, and Shc (28-30). In the dormant molecule, the carboxyl-terminal tail binds as an extended peptide covering a large surface of lobes F2 and F3 of the FERM domain. It was speculated that the tail domain could cause dormancy by either directly blocking partner protein-binding sites and/or by inducing conformational changes in the FERM domain that alter (and inactivate) binding sites (26).

Subsequently, structures reported for the active FERM domains of radixin with and without bound inositol (1, 4, 5)-triphosphate (IP3) (31) and of moesin (32) have given some insight into the structural aspects of activation. The structures of unmasked radixin with or without IP3 (2.8 Å resolution) were highly similar to each other, and comparison to dormant moesin showed local changes in three regions, 138-150, 160-178, and 243-280. The structure of activated moesin (2.7 Å resolution) also revealed shifts in these three regions (32). However, the moesin analysis was complicated by crystal packing interactions that caused large shifts in lobes F1 and -3 and concluded that consistent shifts due to activation were limited to residues 166-170 and 260-264.

Here we present the 2.3 Å resolution crystal structure of the activated FERM domain of ezrin. This represents the first structure for the protein ezrin. Combining this structure with the other two active ERM structures gives us an enhanced ability to identify those structural changes that are due to activation as opposed to sequence differences or crystal packing interactions. Moreover, we go on to document that mobility changes are an important aspect of activation that has not been previously described. Furthermore, our analysis of the active (radixin, moesin, and ezrin) and the dormant (moesin) ERM structures reveals that the tail domain contributes residues that allow the FERM domain to complete its folding, a concept that we refer to as keystone interactions.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Protein Crystallization and Data Collection-- The crystallization of and data collection for the FERM domain of human ezrin (residues 1-297) have been described previously (33). Briefly, the crystals were grown by the hanging drop method using a reservoir solution containing 10-15% (w/v) monomethyl-ether PEG 2000 (Fluka), 15% glycerol (w/v), 10% 2-propanol (w/v), 0.1 M Na-Hepes, (pH 8.1), and they belong to the space group P21 with cell constants a = 48.5 Å, b = 112.8 Å, c = 66.3 Å, beta  = 102.3. Two molecules occupy the asymmetric unit. The diffraction data were collected at -150 °C at the Cornell High Energy Synchrotron Source (CHESS) and processed with the MOSFLM and SCALA programs (CCP4, 1994). Statistics on data collection and refinement are provided in Table I.

Structure Solution and Refinement-- The crystal structure was solved by molecular replacement and refined with the program CNS (34) using the moesin FERM domain (residues 4-296 of PDB entry 1EF1) (26) as a search model. Using a 10.0 to 4.0 Å resolution range, the heights of solutions (the next highest scores in parentheses) for the rotation and translation function were 0.23 (0.07) and 0.22 (0.09), respectively. The crystallographic R-factor was 30.1% after rigid body refinement using data from 25 to 2.3 Å. At this stage the 2Fo-Fc electron density was of sufficient quality to guide the construction of the ezrin FERM molecule using the program O (35). Refinement using amplitudes as the maximum likelihood target involved manual rebuilding, simulated annealing, and conjugated gradient minimization without NCS restraints. An overall anisotropic B-factor correction with a low resolution cutoff of 6 Å yielded B11 = 15 Å2, B22 = -22 Å2, B33 = 6 Å2, and B13 = 8 Å2. Waters were placed initially using the CNS water pick program and later by manual inspection. Simulated annealing omit maps were also used occasionally to check the quality of the model. The final model includes 2 chains of ezrin (A and B), each with residues 2-297 of ezrin, and water molecules. The crystallographic R-factor is 22.3%, and R-free is 27.6% (Table I).

Unusual geometries in well ordered regions of the structure include cis-prolines at residues 75 and 297. Because of weak side chain electron density, residues Ser-148, Arg-151, and Lys-162 were modeled as alanine in both molecules in the asymmetric unit.

Structural Comparisons-- FERM domain structures used for comparison included ezrin chains A and B (from this work), radixin (PDB code 1GE7), radixin bound to IP3 (PDB code 1GE6), moesin (PDB 1E5W), and the dormant moesin bound to the carboxyl-terminal tail domain (PDB code 1EF1). Overlays were accomplished using the programs LSQMAN (36) and DOMOV (37). The overlays reveal that cis-Pro-75 is modeled as a trans-Pro in the radixin structures; we suspect that this is an error and note that it has not influenced our analyses.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Structural Overview-- Crystals of the FERM domain (residues 1-297) of ezrin diffract to 2.3 Å and have two molecules in the asymmetric unit. The structure was solved by molecular replacement, and refinement has led to a model that consists of residues 2 to 297 for each of two chains and 314 water molecules (Table I). The two molecules in the asymmetric unit A and B are in approximately equivalent environments because the non-crystallographic symmetry is nearly a perfect centering operation. Consistent with this, molecules A and B are very similar with a root mean square deviation of Calpha -atoms of 0.4 Å, and all descriptions will refer to molecule A unless specifically noted. The FERM domain is a clover-shaped molecule (Fig. 1A) consisting of three distinct lobes and is globally similar to structures reported previously for ERM proteins (26, 31, 32), merlin (38, 39), and the band-4.1 protein (40). This basic structure has already been well described and will not be elaborated here.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Statistics for x-ray structure determination
Values in parentheses are for the highest resolution bin, from 2.4-2.3 Å.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 1.   Overall structure and mobility of ezrin. A, a ribbon diagram of the ezrin FERM domain and a semitransparent molecular surface illustrates the compact globular cloverleaf-shaped structure possessing three lobes: lobe F1(residues 2-82), lobe F2 (residues 83-195), and lobe F3 (residues 196-297). The ribbon is colored with respect to temperature factor ramped from cold-blue to hot-red for B-factors from <=  20 to >=  80 Å2, respectively. B, temperature-factor plot as a function of residue number for activated FERM domains of ezrin (red), radixin (cyan), and moesin (green), and the dormant FERM domain of moesin (violet). All ribbon figures were prepared with the programs Bobscript and Raster3D (49-51).

Mobility Properties of the FERM Domain-- In contrast, the mobility properties of the FERM domain have not yet been described, although such information is available from protein crystallography in the form of atomic B-factors (also known as temperature factors). Knowledge of mobility along the chain in the activated and dormant structures is likely to provide insight into the mechanism of activation. We first examine the mobility properties in each of the published FERM domains, and then in the next section we compare them to those of dormant moesin to gain insight into the activation process. B-factors are related to the amplitude of motion of the atoms so that in the absence of large model errors, higher B-factors indicate a higher disorder of the atom in question (41). As seen visually in Fig. 1A and graphically in Fig. 1B, the B-factors along the chain of ezrin vary in a complex manner. In particular, local peaks in mobility are mostly associated with loops between secondary structural elements and termini (42). Lobe F1 behaves as a rather tight unit, with relatively small deviations from the mean B-factor, whereas lobes F2 and F3 appear less cohesive, having higher average mobility (Fig. 5) and exhibiting some regions with very high mobilities. These occur near residues 140 in lobe F2 and residues 210 and 260 in lobe F3. In each of these three cases, the loops are not well tethered to the core of the lobe, and the sequences have a high proportion of polar residues.

Most of the mobility features are common among the three activated ERM protein structures (Fig. 1B). Notable differences are limited: ezrin is less mobile near residue 230, radixin is less mobile near residue 260, and moesin is more mobile near residue 160. The first two cases may be explained by crystal contacts because ezrin residue 230 packs against residue 52 of a symmetry mate, and the loop near residue 260 in radixin packs against residues 116 and 234 from a symmetry mate. In the third case, the high B-factors of moesin do not correlate with a packing interaction or a unique sequence feature. However, such a sharp spike in a B-factor plot is sometimes caused by a model error (43), which is plausible in this case because it is a mobile region in a medium resolution (2.7 Å) structure, and three residues have rare phi ,psi -angles, (-72,-169) for Leu-158, (77,-19) for Glu-159, and (-147,28) for Lys-161.

Conformational and Mobility Changes Associated with Activation-- To best define the conformational and mobility changes that are associated with activation, we have compared the six FERM domain structures available for ERM proteins: dormant moesin, activated radixin, the activated radixin-IP3 complex, activated moesin, and molecules A and B of activated ezrin presented here. These make a total of five activated and one dormant molecule. The pair of radixin structures are very similar, as are the pair of ezrin structures; indeed, they are not truly independent from one another because they are in equivalent crystallographic environments. Thus, the radixin-IP3 complex and ezrin molecule B are left out of the systematic analyses because they do not add significant new information.

Conformational Changes Associated with Activation-- Both visual (Fig. 2) and quantitative (Fig. 3A) analyses of mobile regions of all of the activated structures with the dormant moesin structure reveal that the activated ezrin and radixin structures cluster together but that the activated moesin structure has large differences in lobes F1 and F3. These differences are a result of a movement of moesin lobes F1 and F3 toward each other. This movement has been ascribed to a crystal packing effect (32) so that the activated moesin structure is less reliable for defining movements associated with activation. Combining information from the ezrin- and radixin-activated structures allows us to locate regions where the pair deviate more from the dormant structure than from each other. This provides a striking delineation of residues that move significantly upon activation (Fig. 3B). The regions implicated are major shifts of residues 130-150, 155-180, and 240-270 and small but significant shifts near residues 70 and 210. The larger shifts are similar to those identified by Hamada et al. (31) in their study of the FERM domain of activated radixin, but the smaller shifts have not been noted before.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 2.   Overlay of the FERM domains of the ERM family members. Superposition of the FERM domains of ezrin (red), radixin (cyan), and active moesin (green) onto dormant moesin (violet) bound to the inhibitory carboxyl-terminal tail (ghostly yellow). To be most informative, these overlays have been done as described in Fig. 3B.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   Quantitation of the structural shifts associated with activation. A, C-alpha root mean square deviation of each activated FERM domain compared with the dormant moesin domain. Ezrin (red), radixin (cyan), and moesin (green). The ezrin and radixin plots are highly similar, but the moesin plot has many large unique features. B, the average mobility differences between two activated structures (ezrin and radixin, violet) compared with the average mobility between activated and dormant structures (activated ezrin/dormant moesin and activated radixin/dormant moesin, blue) is shown. Regions where the blue line rises above the violet line define regions that appear to have a significant conformational change upon activation. For the superimpositions used to generate panel B, residues clearly involved in significant local movements (residues 131-174 and 241-269) were removed from the calculations. Overlays were calculated using LSQMAN (36).

To dissect conformational changes into components due to rigid lobe rotations and those that are local in nature, we calculated independent overlays for each lobe. The resulting rigid lobe rotations were very small, ranging from 0.5° to 1.5°, and the resulting plot of local shifts was virtually unchanged from Fig. 3. An unexpected benefit of this lobe-wise analysis is that treatment of the activated moesin structure in this manner removes the crystal packing affects (lobe rotations of 4-8°), so that local changes in moesin agree with those seen in ezrin and radixin (data not shown). The following three paragraphs summarize the conformational changes undergone by each lobe during activation.

The rigid body movements of lobe F1 (residues 4-80) are very small, involving a rotation ranging from 0.5-0.7° for the ezrin and radixin structures. The only significant local structural change, at residues 73-75 (Fig. 3B), involves a turn just after strand beta 5. This turn is far from all other changes and does not appear to be related to activation. Also, because activated moesin follows dormant moesin more closely, we suspect that this shift is due to sequence changes, because ezrin and radixin have Asn-74 and Gln-77, whereas moesin has Ser-74 and Leu-77.

For lobe F2 (residues 88-199), the lobe rotation is again small, ranging from 1.2-1.5°. However, major local changes (up to 3-Å shifts) occur for residues 132-151 and 155-177 (Fig. 3B). As seen in Fig. 4A, these changes involve coordinated shifts of the last turn of helix B and the following loop and of all of helix C (maximal at its amino terminus). A look at side chain positions reveals some clear ways that these movements associated with activation can compensate for the removal of helix A of the carboxyl-terminal tail. The three most notable cases are the shift of Trp-175 to fill the pocket vacated by Leu-525, a flip of the side chain of Arg-171 to help fill the space vacated by Leu-529, and a shift in the side chain of Trp-168, as well as the whole of residues 160-162, to fill space vacated by residues 533 to 537 (Fig. 4A). Residues 132-151 pack onto the backside of lobe F2 helix C, and their motion appears to be due to being pulled along by the shifting helix C. In addition to many nonspecific contacts in this core, a key side chain connecting helix C to this chain segment is the buried His-176 whose side chain hydrogen bonds to Tyr-146-OH and Gly-135-O


View larger version (74K):
[in this window]
[in a new window]
 
Fig. 4.   Close-ups of structural shifts associated with activation and their relation to the loss of the carboxyl-terminal tail. A, lobe F2 of ezrin (red) compared with the dormant moesin (violet)-carboxyl-terminal tail (ghostly yellow) complex. Large local shifts of the B-C loop and helix C are visible, as these residues collapse to fill in space that had been occupied by carboxyl-terminal tail residues. B, like panel A, but for Lobe F3. Visible is the collapsing of the beta 1therefore beta 2 hairpin and the beta 5therefore beta 6therefore beta 7 subdomain into the space vacated by helix D of the carboxyl-terminal tail.

For lobe F3, the rigid body rotation is again small, only 0.7-1.4°. Notable local changes in the conformation of lobe F3 include the small shifts of residues 211-213 and the extensive shifts of residues 240-267, which have a maximal shift of nearly 6 Å at residue 261. These movements can be described as mainly a collapsing of the beta 1-beta 2 hairpin and the beta -meander subdomain (beta 5, -6, -7) into the space occupied by helix D of the carboxyl-terminal tail (Fig. 4B). As with lobe F2, it is possible to describe some clear ways that these movements can be seen to compensate for the removal of helix D of the carboxyl-terminal tail. The movement of the beta -meander seems tied to a shift of Phe-267 to fill the space that had been occupied by Phe-574 and so Pro-265 and Asp-266 can fill the space occupied by Ile-571. Similarly, the side chain of Lys-237 flips directions so that it fills the space occupied by Met-577. Interestingly, the change of Lys-237 seems correlated with flips of the side chains of Glu-229 and Asn-231 (Fig. 4B).

Mobility Changes because of Activation-- A broad comparison of the mobilities of the activated structures with those of dormant moesin reveals that the overall mobility of lobe F1 remains similar during activation, but the mobilities of lobes F2 and F3 as a whole increase significantly (Fig. 5). This results in an inversion such that the lobe F1 goes from being the least well ordered lobe to being the most well ordered lobe. The transition occurs near residue 88 (see Fig. 1B), which is about halfway through the linker between lobes F1 and F2 (26). Three regions have very dramatic increases in mobility; these are near residues 140, 210, and 265, mentioned above as the three regions that are highly mobile in the activated structures. For the loop near residue 140, the case is less clear that this increase in mobility is associated with activation, because these residues are not in direct contact with the carboxyl-terminal tail in the dormant structure and we do not see any structural changes that would clearly cause them to become more mobile. One plausible explanation is that these residues are actually already rather mobile in the dormant moesin structure but that a crystal packing interaction in that crystal (residues 141-149 pack against residues 560-565 in another molecule) damped their natural mobility. We conclude that residues 135-145 are very mobile in the activated FERM domain, but we must leave open the question of how much their mobility increases upon activation.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Significant disordering upon activation. The average B-factors for each lobe are shown for the dormant FERM domain structure (dash, square) and the three activated FERM domains: ezrin (thin, diamond), radixin (thick, square), and moesin (thickest, triangle). Details of the B-factor variations within each lobe for each of the proteins are shown in Fig. 1B.

Inspection of the dormant moesin complex structure (26) indicates that the increases in mobility near residues 212 and 265 can be directly traced to the removal of helix D of the carboxyl-terminal tail. In the first case, residues 210, 211, 212, and 214 all make H-bonds to residues 574-577 (the last four residues of the inhibitory tail), and Leu-216 is buried by the side chain of Met-577 in the complex (see Fig. 6B). In the second case, the key seems to be that Phe-267 of beta -strand 7 was well buried by helix D, but with helix D absent Phe-267 is no longer pinned in place, which increases the lever arm around which the loop near residue 260 can fluctuate.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 6.   The keystone view of carboxyl-terminal tail interactions with lobes F2 and F3. Both panels show the structure of the dormant moesin-carboxyl-terminal tail complex. A, stereoview of lobe F2 (violet) with helix A of the carboxyl-terminal tail (yellow). B, stereoview of lobe F3 (violet) with the helix D of the carboxyl-terminal tail (yellow). For context, the complete backbone trace of the FERM domain lobe is shown as a ribbon, and selected side chains lining the binding pocket are shown. Selected hydrogen bonds are shown as dashed lines. Note in both cases how the carboxyl-terminal tail contributes intimately to the hydrophobic core of the domain.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The crystal structure of ezrin presented here completes the picture, so that a structure is now available for the FERM domains of each of the three ERM proteins. Also, the 2.3-Å resolution of this structure provides details such as solvent structure, not visible in the lower resolution structures of activated moesin (2.7 Å) or radixin (2.8 Å). Because the FERM domain fold is already well characterized, one major value of this structure derives from the opportunity to compare all the ERM structures to differentiate which structural changes are because of activation and which are because of crystal packing interactions or sequence differences among the ERM proteins. A second major value of this work is that the analyses of B-factors reveals that, in addition to conformational changes, FERM domain activation involves large increases in the flexibility of lobes F2 and F3. This increase in flexibility has important bearing on the energetics and specificity of ligand binding (see below).

The Extent and Origins of Conformational Changes-- The use of the quantitative variation in the activated structures as a reference for defining what changes are significant is powerful in that it allows a quantitative, unambiguous delineation of a set of residues that show significant motion (Fig. 3B). However, it is worth noting that because of the limited resolution of the structures and possible variations among activated structures due to crystal packing interactions and intrinsic chain mobility, we do not expect the analysis to reliably reveal changes in structure much smaller than about 1 Å, even though such changes must exist.

Our analysis confirms the validity of the conformational changes due to activation that were proposed based on the activated radixin structure (31) as opposed to the much more limited set of changes highlighted in the analysis of the activated moesin structure (32). These changes are all local in nature, involving virtually no relative movements of the lobes as a whole. This is in line with the expectation of Pearson et al. (26) that the relative positions of the three FERM domain lobes are rather well fixed. However, it must be borne in mind that the >5° lobe rotations induced by a crystal packing interaction in the moesin structure show that significant motions can occur upon the binding of an appropriate ligand.

But what triggers these changes? Both the conformational and mobility changes associated with the activation of ERM proteins appear to be concretely related to the loss of interactions with parts of the autoinhibitory carboxyl-terminal tail, in particular helix A and the AB loop (Fig. 4A), helix D (Fig. 4B), and possibly strand beta 1 (see Fig. 2). The effect of the loss of strand beta 1 of the carboxyl-terminal tail is not clear because the residues in contact with that strand (e.g. Ile-245, Ile-248) do move but their movement can already be related to the loss of helix D. The loss of other parts of the carboxyl-terminal tail are not visibly associated with conformational changes even though they cover about half the surface area buried by the carboxyl-terminal tail. Indeed, of 57 FERM domain residues highlighted by Pearson et al. (Fig. 4 of Ref. 26) as involved in carboxyl-terminal tail binding, only 28 of them are in the regions that change upon activation.

The Role of IP3 Binding in Activation-- It was proposed by Hamada et al.(31), based on the radixin-IP3 complex, that IP3 binding pushes helix A to widen the cleft between lobes F1 and F3 and that this movement in helix A induces the other shifts in lobe F3 and leads to activation. The similarity of activated ezrin to activated radixin (with or without IP3) strengthens the argument presented by Edwards and Keep (32) that the movements of lobe F3 are not a direct outcome of IP3 binding but are simply related to the loss of the carboxyl-terminal tail. It could be that IP3 would also force these changes to occur (and thus stimulate activation), but there is no evidence that that is true. At a more fundamental level, one important outstanding question regarding the relevance of the IP3-radixin complex is whether IP3 can substitute for PIP2 in activation experiments. We are not aware of experiments that answer this question, and if IP3 does not serve as an activator then results about its binding site may not be informative about how PIP2 activates ERM proteins. In this regard, the mutagenesis results of Barret et al. (44), though not conclusive in themselves, support the idea that activation by PIP2 may be more complex than the crystallographically defined IP3 binding site would imply.

Helices A and D of the Carboxyl-terminal Tail as Keystone Binding Partners-- As we see it, the high degree of disordering that occurs upon activation indicates that lobes F2 and F3 of the FERM domain can be viewed as incompletely folded domains; that is, lobes F2 and F3 need residues from the carboxyl-terminal tail (or some other source) to be contributed to their hydrophobic cores so they can complete their folding (Fig. 6). In the case of lobe F2, Leu-525 and Leu-529 of helix A insert into the core to complete the fold, and in the case of lobe F3, Ile-571, Phe-574, and Met-577 of helix D insert to do the same. This type of interaction suggests that the carboxyl-terminal tail residues and the associated helices that hold them serve to complete and stabilize the structures of lobes F2 and F3 much like a keystone completes and stabilizes the structure of an arch. Although it was not called a keystone interaction, a classic example in which an incompletely folded protein requires an external piece to complete its folding is provided by bovine trypsinogen (45). As synthesized, the inactive protease precursor trypsinogen has a highly mobile incompletely folded "activation domain," and upon cleavage at Ile-16, the new amino terminus tucks inside the protein, as a keystone, to make many interactions that drive the protein to finish folding.

The idea of a keystone interaction is quite different from the common experience and expectation that protein-protein interactions will involve the interactions of preformed surfaces of fully folded proteins. This more intimate mode of interaction brings with it a much greater potential for high affinity binding with very low rates of dissociation, as is seen for the dormant ERM proteins (26). It is easy to see how such high affinity binding interactions would be highly desirable for cytoskeletal proteins; they serve a structural role where it is desirable for them to not be in a dynamic on-off equilibrium but securely anchored to their partner, not releasing even once until a signal for reorganization is received. Thus, such keystone interactions may be a theme that will also be seen in other cytoskeletal proteins that are regulated by masking (15-18).

Although no work has yet been published that defines the sites at which the FERM domain will interact with its partner proteins, our observation brings with it the clear prediction that the sites to which carboxyl-terminal tail helices A and D bind will be high affinity sites for partner proteins. Although the flexibility of the activated lobes F2 and F3 makes it conceivable that a variety of structures might bind as keystone molecules, the most natural prediction is that some partner protein will have a recognition helix that closely mimics helix A and binds to lobe F2 and some will have a recognition helix that closely mimics helix D and binds to lobe F3. In the latter case, given the manifold interactions of the 210 turn with the C terminus of helix D (Fig. 6B), this pocket may even be specific for a carboxyl-terminal helix. Although these are clear predictions for where some partner proteins will bind, these need not be the only recognition sites on the FERM domain. Indeed, the loss of the other parts of the carboxyl-terminal tail do not appear to influence the integrity of the structure as much, although they still may make significant contributions to binding affinity.

Regulation by Phosphorylation-- Another possible contributor to activation that has not received much attention in structural studies is the phosphorylation of Tyr-146. This residue has been reported to be phosphorylated in ezrin during epidermal growth factor stimulation of cells (46), and it may also occur in radixin because radixin is reported to be phosphorylated by the platelet-derived growth factor receptor (47) at a site that has not been mapped. Whether the phosphorylation occurs in the dormant or activated state and what physiological role it has are as yet unanswered questions (48). In the original structure of dormant moesin, the phosphorylation Tyr-146 was a mystery because Tyr-146 was fully buried in a well ordered part of the structure. The very high mobility of this region in the activated FERM proteins suggests that the phosphorylation of Tyr-146 could readily occur because the loop containing Tyr-146 probably undergoes rapid local unfolding to become accessible to a kinase. With regard to its role in activation, it is clear that if Tyr-146 is phosphorylated, the folding of the 130-150 loop that surrounds His-176 will be disrupted. Lobe F2 will not be able to adopt its normal structure and probably will not interact as effectively with the carboxyl-terminal tail or other partner proteins that bind at this site. In this way, phosphorylation at Tyr-146 of the dormant protein could lead to dissociation of the carboxyl-terminal tail to activate the rest of the FERM domain. However, phosphorylation at Tyr-146 of the active protein would serve to differentially deactivate the putative binding site on lobe F2. Another attractive possibility is that the phosphorylation of Tyr-146 could lead to alternate signaling pathways via association with proteins containing SH2 (src-homology 2) or phosphotyrosine binding domains and thus may serve as a scaffold to recruit such proteins to the plasma membrane. This provides the first concrete proposal for how the FERM domain may be activated/deactivated with respect to specific partner proteins.

    ACKNOWLEDGEMENTS

We thank Matt Pearson for use of coordinates before publication for solving the molecular replacement problem. We also thank Dan Thiel, Marian Szebenyi, and Lana Walsh for beam time at CHESS and the entire CHESS staff for assistance during data collection. We thank Cindy Westmiller for excellent secretarial help.

    FOOTNOTES

* This work is based upon research conducted at the Cornell High Energy Synchrotron Source (CHESS), which is supported by the National Science Foundation and NIGMS, National Institutes of Health under award DMR 9713424. This work was supported by National Institutes of Health Grants GM36652 (to A. P. B.) and 2 R01 GM40654 (to R. A. C.) and NIH Training Grant GM07273 (to W. J. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and the structure factors (code 1NI2) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

§ Present address: Dept. of Physiology and Biophysics, SUNY, HSC, Stony Brook, NY 11794-8116.

|| To whom correspondence may be addressed. Tel.: 607-255-5713; Fax: 607-255-6249; E-mail: apb5@cornell.edu.

§§ To whom correspondence may be addressed. Tel.: 541-737-3200; Fax: 541-737-0481; E-mail: karplusp@ucs.orst.edu.

Published, JBC Papers in Press, November 11, 2002, DOI 10.1074/jbc.M210601200

    ABBREVIATIONS

The abbreviations used are: ERM, ezrin, radizin, moesin; IP3, inositol-triphosphate; PIP2, phosphatidylinositol(4,5)-bisphosphate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Bretscher, A. (1983) J. Cell Biol. 97, 425-432[Abstract]
2. Gould, K. L., Cooper, J. A., Bretscher, A., and Hunter, T. (1986) J. Cell Biol. 102, 660-669[Abstract]
3. Tsukita, S., Hieda, Y., and Tsukita, S. (1989) J. Cell Biol. 108, 2369-2382[Abstract]
4. Funayama, N., Nagafuchi, A., Sato, N., and Tsukita, S. (1991) J. Cell Biol. 115, 1039-1048[Abstract]
5. Lankes, W. T., and Furthmayr, H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8297-8301[Abstract]
6. Tsukita, S., and Yonemura, S. (1999) J. Biol. Chem. 274, 34507-34510[Free Full Text]
7. Bretscher, A., Edwards, K., and Fehon, R. G. (2002) Nat. Rev. Mol. Cell. Biol. 3, 586-599[CrossRef][Medline] [Order article via Infotrieve]
8. Tsukita, S., Oishi, K., Sato, N., Sagara, J., Kawai, A., and Tsukita, S. (1994) J. Biol. Chem. 126, 391-401
9. Heiska, L., Alfthan, K., Gronholm, M., Vilja, P., Vaheri, A., and Carpen, O. (1998) J. Biol. Chem. 273, 21893-21900[Abstract/Free Full Text]
10. Gautreau, A., Poullet, P., Louvard, D., and Arpin, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7300-7305[Abstract/Free Full Text]
11. Hirao, M., Sato, N., Kondo, T., Yonemura, S., Monden, M., Sasaki, T., Takai, Y., and Tsukita, S. (1996) J. Cell Biol. 135, 37-51[Abstract]
12. Reczek, D., and Bretscher, A. (1998) J. Biol. Chem. 273, 18452-18458[Abstract/Free Full Text]
13. Lamb, R. F., Roy, C., Diefenbach, T. J., Vinters, H. V., Johnson, M. W., Jay, D. G., and Hall, A. (2000) Nat. Cell Biol. 2, 281-287[CrossRef][Medline] [Order article via Infotrieve]
14. Gary, R., and Bretscher, A. (1995) Mol. Biol. Cell 6, 1061-1075[Abstract]
15. Johnson, R. P., and Craig, S. W. (2000) J. Biol. Chem. 275, 95-105[Abstract/Free Full Text]
16. Gilmore, A. P., and Burridge, K. (1996) Nature 381, 531-535[CrossRef][Medline] [Order article via Infotrieve]
17. Kim, A. S., Kakalis, L. T., Abdul-Manan, N., Liu, G. A., and Rosen, M. K. (2000) Nature 404, 151-158[CrossRef][Medline] [Order article via Infotrieve]
18. Alberts, A. S. (2001) J. Biol. Chem. 276, 2824-2830[Abstract/Free Full Text]
19. Turunen, O., Wahlstrom, T., and Vaheri, A. (1994) J. Cell Biol. 126, 1145-1453
20. Dransfield, D. T., Bradford, A. J., Smith, J., Martin, M., Roy, C., Mangeat, P. H., and Goldenring, J. R. (1997) EMBO J. 16, 35-43[Abstract/Free Full Text]
21. Matsui, T., Maeda, M., Doi, Y., Yonemura, S., Amano, M., Kaibuchi, K., Tsukita, S., and Tsukita, S. (1998) J. Cell Biol. 140, 647-657[Abstract/Free Full Text]
22. Pietromonaco, S. F., Simons, P. C., Altman, A., and Elias, L. (1998) J. Biol. Chem. 273, 7594-7603[Abstract/Free Full Text]
23. Simons, P. C., Pietromonaco, S. F., Reczek, D., Bretscher, A., and Elias, L. (1998) Biochem. Biophys. Res. Commun. 253, 561-565[CrossRef][Medline] [Order article via Infotrieve]
24. Niggli, V., Andreoli, C., Roy, C., and Mangeat, P. (1995) FEBS Lett. 376, 172-176[CrossRef][Medline] [Order article via Infotrieve]
25. Yonemura, S., Matsui, T., and Tsukita, S. (2002) J. Cell Sci. 115, 2569-2580[Abstract/Free Full Text]
26. Pearson, M. A., Reczek, D., Bretscher, A., and Karplus, P. A. (2000) Cell 101, 259-270[Medline] [Order article via Infotrieve]
27. Kragelund, B. B., Andersen, K. V., Madsen, J. C., Knudsen, J., and Poulsen, F. M. (1993) J. Mol. Biol. 230, 1260-1277[CrossRef][Medline] [Order article via Infotrieve]
28. Ferguson, K. M., Lemmon, M. A., Schlessinger, J., and Sigler, P. B. (1994) Cell 79, 199-209[Medline] [Order article via Infotrieve]
29. Soisson, S. M., Nimnual, A. S., Uy, M., Bar-Sagi, D., and Kuriyan, J. (1998) Cell 95, 259-268[Medline] [Order article via Infotrieve]
30. Zhou, M. M., Ravichandran, K. S., Olejniczak, E. F., Petros, A. M., Meadows, R. P., Sattler, M., Harlan, J. E., Wade, W. S., Burakoff, S. J., and Fesik, S. W. (1995) Nature 378, 582-592
31. Hamada, K., Shimizu, T., Matsui, T., Tsukita, S., and Hakoshima, T. (2000) EMBO J. 19, 4449-4462[Abstract/Free Full Text]
32. Edwards, S. D., and Keep, N. H. (2001) Biochemistry 40, 7061-7068[Medline] [Order article via Infotrieve]
33. Smith, W. J., and Cerione, R. A. (2002) Acta Crystallogr. Sec. D 58, 1359-1361[CrossRef][Medline] [Order article via Infotrieve]
34. Brunger, A. T., Adams, P. D., Clore, G. M., Gros, P., Grosse-Kuntsleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. (1998) Acta Crystallogr. Sec. D 54, 905-921[CrossRef][Medline] [Order article via Infotrieve]
35. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sec. A 47, 110-119[CrossRef][Medline] [Order article via Infotrieve]
36. Kleywegt, G. J. (2000) Acta Crystallogr. Sec. D 56, 249-265[CrossRef][Medline] [Order article via Infotrieve]
37. Lu, G. (1996) Protein Data Bank Quarterly Newsletter 78, 10-11
38. Kang, B. S., Cooper, D. R., Devedjiev, Y., Derewenda, U., and Derewenda, Z. S. (2002) Acta Crystallogr. Sec. D 58, 381-391[CrossRef][Medline] [Order article via Infotrieve]
39. Shimizu, T., Seto, A., Maita, N., Hamada, K., Tsukita, S., Tsukita, S., and Hakoshima, T. (2002) J. Biol. Chem. 277, 10332-10336[Abstract/Free Full Text]
40. Han, B. G., Nunomura, W., Takakuwa, Y., Mohandas, N., and Jap, B. K. (2000) Nat. Struct. Biol. 7, 871-875[CrossRef][Medline] [Order article via Infotrieve]
41. Sternberg, M. J., Grace, D. E., and Phillips, D. C. (1979) J. Mol. Biol. 130, 231-252[Medline] [Order article via Infotrieve]
42. Karplus, P. A., and Schulz, G. E. (1987) J. Mol. Biol. 195, 701-729[Medline] [Order article via Infotrieve]
43. Jensen, L. H. (1997) Methods Enzymol. 277, 353-366[CrossRef]
44. Barret, C., Roy, C., Montcourrier, P., Mangeat, P., and Niggli, V. (2000) J. Cell Biol. 151, 1067-1079[Abstract/Free Full Text]
45. Brunger, A. T., Huber, R., and Karplus, M. (1987) Biochemistry 26, 5153-5162[Medline] [Order article via Infotrieve]
46. Kreig, J., and Hunter, T. (1992) J. Biol. Chem. 267, 19258-19265[Abstract/Free Full Text]
47. Zhang, F. X., and Hutchins, J. B. (1997) Brain Res. Dev. Brain Res. 99, 216-225[Medline] [Order article via Infotrieve]
48. Bretscher, A. (1999) Curr. Opin. Cell Biol. 11, 109-116[CrossRef][Medline] [Order article via Infotrieve]
49. Kraulis, P. J. (1991) J. Applied Crystallogr. 24, 946-950[CrossRef]
50. Esnouf, R. M. (1997) J. Mol. Graph. Model. 15, 132-134[CrossRef][Medline] [Order article via Infotrieve]
51. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505-524
52. Diederichs, K., and Karplus, P. A. (1997) Nat. Struct. Biol. 4, 269-275[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.